Sensei Biotherapeutics, Inc. SNSE
We take great care to ensure that the data presented and summarized in this overview for Sensei Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNSE
View all-
Newtyn Management, LLC New York, NY930KShares$1.48 Million0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA574KShares$912,4110.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny211KShares$335,4900.0% of portfolio
-
Geode Capital Management, LLC Boston, MA136KShares$216,7450.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX113KShares$179,5110.0% of portfolio
-
Bank Of America Corp Charlotte, NC90.8KShares$144,3130.0% of portfolio
-
Black Rock Inc. New York, NY33.6KShares$53,3950.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny32.6KShares$51,8130.0% of portfolio
-
Northern Trust Corp Chicago, IL26KShares$41,4170.0% of portfolio
-
State Street Corp Boston, MA25.8KShares$40,9800.0% of portfolio
Latest Institutional Activity in SNSE
Top Purchases
Top Sells
About SNSE
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Insider Transactions at SNSE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 15
2024
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-4.83%
|
$0
$0.79 P/Share
|
Feb 15
2024
|
Erin Colgan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-5.1%
|
$0
$0.79 P/Share
|
Feb 15
2024
|
John Celebi PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,891
-5.29%
|
$0
$0.79 P/Share
|
Sep 11
2023
|
John Celebi PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.45%
|
$0
$0.85 P/Share
|
Jul 31
2023
|
Cambrian Bio Pharma Inc |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,587,302
-30.29%
|
$1,587,302
$1.26 P/Share
|
Jul 31
2023
|
James Peyer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,587,302
-30.29%
|
$1,587,302
$1.26 P/Share
|
Jul 10
2023
|
Samuel Broder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
Jul 10
2023
|
Thomas G Ricks Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
Jul 10
2023
|
William R Ringo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+16.03%
|
-
|
Jul 10
2023
|
Kristian Humer Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
Jul 10
2023
|
Deneen Vojta Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
Jul 10
2023
|
Jessie English Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
Jul 10
2023
|
Bob Holmen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+14.86%
|
-
|
Jul 10
2023
|
Cambrian Bio Pharma Inc |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+0.09%
|
-
|
Jul 10
2023
|
James Peyer |
BUY
Grant, award, or other acquisition
|
Indirect |
4,466
+0.09%
|
-
|
Jun 01
2023
|
Apeiron Investment Group Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,441,661
-100.0%
|
$3,441,661
$1.58 P/Share
|
Feb 23
2023
|
Apeiron Investment Group Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,200
+0.04%
|
$2,200
$1.61 P/Share
|
Feb 15
2023
|
Patrick Stephen Gallagher Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,383
-21.56%
|
$9,383
$1.5 P/Share
|
Feb 15
2023
|
Erin Colgan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,943
-13.85%
|
$10,943
$1.5 P/Share
|
Feb 15
2023
|
John Celebi PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,492
-15.61%
|
$20,492
$1.5 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 40.2K shares |
---|---|
Open market or private purchase | 500 shares |
Open market or private sale | 3.44M shares |
---|---|
Sale (or disposition) back to the issuer | 3.17M shares |
Payment of exercise price or tax liability | 12.4K shares |